Research Details

Abstract

Allison Watkins, senior director of Merck's Vaccines Division, needed to decide on the pricing of Gardasil, Merck's newest vaccine and one of the company's most important product launches of the year. The outside consulting firm she had hired to recommend a price for Gardasil had suggested a price of $120 per dose (or $360 per person, as each person required three doses over six months to achieve adequate immunity). The Gardasil marketing team disagreed about this recommended price; some thought it was clearly too high, whereas others said it was too low. The latter group argued that Merck would be missing a major opportunity by setting the price at such a low level. Watkins now needed to decide whether to follow the consulting firm's recommendation or to set a different price.

Type

Case

Author(s)

Timothy Calkins, Megha Vora

Date Published

02/23/2009

Citations

Calkins, Timothy, and Megha Vora. Merck: Pricing Gardasil. Case 5-308-505 (KEL400).

PREVIEW or BUY